This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Zemcelpro is used to treat patients that require allogeneic hematopoietic stem cell transplantation following chemotherapy or radiotherapy when no other type of suitable donor cells is available. Two generic drugs were also approved.
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. 5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. June 21, 2024. Hemasphere.
A group of experts will present an encore abstract titled " Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using Real-World Data " at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here. Subscribe Now!
The field is expanding into autoimmune diseases, with nononcology trials representing 51% of the pipeline by late 2024. Development Trends: Oncology at the Forefront Gene therapy currently ranks third among therapeutic focus areas, with 2151 compounds in development in 2024 ( Figure ).
August 8, 2024. Updated January 19, 2024. LinkedIn Workplace Learning Report 2024. American Oncology Network. Accessed May 15, 2025. How your oncology peers manage the complexities of care. Oncology Live ®. December 13, 2018. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development.
After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects. January 17, 2024. 2024;25(1):336. doi:10.1186/s13063-024-08174-x 7. Pharmacy Times.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The focus on identifying the ideal drug dosage is not new.
Chemotherapy agents: Chemotherapy agents can lead to constipation in a variety of ways such as slowing the movements of the intestinal tract or creating inflammation that disrupts digestive function. Be sure to work with your doctor or practitioner to determine the right supplements and dosages for you. Accessed June 6, 2023.
Exclusive: Regulator extends part suspension of licence to July 2024 after IT blunder led to incorrect dosage of cancer treatment A private health company paid millions by the NHS has failed to fix safety defects that led to the death of a cancer patient, the Guardian can reveal.
FDA analyzed anorexia related to a medical condition, anxiety, epilepsy, inflammatory bowel disease, nausea and chemotherapy-induced vomiting, pain, and post-traumatic stress disorder. US poised to ease restrictions on marijuana in historic shift, but it’ll remain controlled substance (Apr. treaty obligations in rescheduling. 21 U.S.C. §
Rescheduling Recommendation, 2024 FDA’s 2023 analysis and recommendation finally came to light when Texas attorney Matt Zorn posted it on his website a week ago. Thirty-eight states currently authorize marijuana in different dosage formulations for specific qualifying medical conditions. chemotherapy-induced), and pain.
It acts as a mobilization agent and should be injected subcutaneously with dosage depending on body weight. It is the only drug in its class of chemotherapy and is developed from the natural substance found in a sea sponge. The stem cells are then collected and subsequent autologous transplantation into the patients.
On Thursday, May 16, 2024 , the Attorney General issued a Notice of Proposed Rulemaking (“NPRM”) to initiate rulemaking proceedings to reschedule marijuana. The NPRM was signed by the Attorney General but published by DEA in the Federal Register on May 21, 2024. 44,597 (May 21, 2024). chemotherapy-induced), and pain.
In a press release, Theramex estimated that more than 1000 postmenopausal women in Scotland would be eligible for treatment, with SMC’s recommendation following a previous one made in August 2024 by the National Institute for Health and Care Excellence (NICE) governing abaloparatide’s status in England, Wales, and Northern Ireland (1).
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content